311 related articles for article (PubMed ID: 15978698)
1. Clinical impact and relevance of antibiotic resistance.
French GL
Adv Drug Deliv Rev; 2005 Jul; 57(10):1514-27. PubMed ID: 15978698
[TBL] [Abstract][Full Text] [Related]
2. Economics of antibiotic resistance.
Sipahi OR
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):523-39. PubMed ID: 18662118
[TBL] [Abstract][Full Text] [Related]
3. New antimicrobial agents for the treatment of bacterial infections in cancer patients.
Rolston KV
Hematol Oncol; 2009 Sep; 27(3):107-14. PubMed ID: 19569253
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial stewardship: bridging the gap between quality care and cost.
Goff DA
Curr Opin Infect Dis; 2011 Feb; 24 Suppl 1():S11-20. PubMed ID: 21200180
[TBL] [Abstract][Full Text] [Related]
5. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
Kusowska J
Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
[TBL] [Abstract][Full Text] [Related]
6. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
Kusowska J
Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
[TBL] [Abstract][Full Text] [Related]
7. The impact of antimicrobial resistance on health and economic outcomes.
Cosgrove SE; Carmeli Y
Clin Infect Dis; 2003 Jun; 36(11):1433-7. PubMed ID: 12766839
[TBL] [Abstract][Full Text] [Related]
8. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome.
Nseir S; Di Pompeo C; Cavestri B; Jozefowicz E; Nyunga M; Soubrier S; Roussel-Delvallez M; Saulnier F; Mathieu D; Durocher A
Crit Care Med; 2006 Dec; 34(12):2959-66. PubMed ID: 17012911
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic burden of antimicrobial resistance.
Maragakis LL; Perencevich EN; Cosgrove SE
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):751-63. PubMed ID: 18847410
[TBL] [Abstract][Full Text] [Related]
10. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment.
McDonald LC
Clin Infect Dis; 2006 Jan; 42 Suppl 2():S65-71. PubMed ID: 16355319
[TBL] [Abstract][Full Text] [Related]
11. Current challenges in the management of the infected patient.
Nicolau DP
Curr Opin Infect Dis; 2011 Feb; 24 Suppl 1():S1-10. PubMed ID: 21200179
[TBL] [Abstract][Full Text] [Related]
12. Future pharmacoeconomic criteria for the treatment of infections.
Milkovich G
Int J Antimicrob Agents; 2009 Jul; 34 Suppl 1():S12-4. PubMed ID: 19560668
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic resistance as a major public health concern: epidemiology and economic impact.
Ciorba V; Odone A; Veronesi L; Pasquarella C; Signorelli C
Ann Ig; 2015; 27(3):562-79. PubMed ID: 26152543
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of the emergence of bacterial resistance in the hospital environment.
Hosein IK; Hill DW; Jenkins LE; Magee JT
J Appl Microbiol; 2002; 92 Suppl():90S-7S. PubMed ID: 12000618
[TBL] [Abstract][Full Text] [Related]
15. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
16. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
17. Resistance to antibiotics: are we in the post-antibiotic era?
Alanis AJ
Arch Med Res; 2005; 36(6):697-705. PubMed ID: 16216651
[TBL] [Abstract][Full Text] [Related]
18. Cost of Gram-negative resistance.
Evans HL; Lefrak SN; Lyman J; Smith RL; Chong TW; McElearney ST; Schulman AR; Hughes MG; Raymond DP; Pruett TL; Sawyer RG
Crit Care Med; 2007 Jan; 35(1):89-95. PubMed ID: 17110877
[TBL] [Abstract][Full Text] [Related]
19. Economic aspects of antimicrobial therapy of acute exacerbations of COPD.
Simoens S; Decramer M; Laekeman G
Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975
[TBL] [Abstract][Full Text] [Related]
20. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs.
Sturkenboom MC; Goettsch WG; Picelli G; in 't Veld B; Yin DD; de Jong RB; Go PM; Herings RM
Br J Clin Pharmacol; 2005 Oct; 60(4):438-43. PubMed ID: 16187977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
